Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin. [electronic resource] by
- Maeda, Akimitsu
- Ando, Hitoshi
- Ura, Takashi
- Muro, Kei
- Aoki, Masahiro
- Saito, Ken
- Kondo, Eisaku
- Takahashi, Shinji
- Ito, Yuko
- Mizuno, Yasunari
- Fujimura, Akio
Producer: 20170918
In:
Anticancer research vol. 37
Availability: No items available.
|
|
7.
|
Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. [electronic resource] by
- Maeda, Akimitsu
- Irie, Kei
- Ando, Hitoshi
- Hasegawa, Ayako
- Taniguchi, Hiroya
- Kadowaki, Shigenori
- Muro, Kei
- Tajika, Masahiro
- Aoki, Masahiro
- Inaguma, Kazuhide
- Kajita, Masaki
- Fujimura, Akio
- Fukushima, Shoji
Producer: 20191112
In:
Cancer chemotherapy and pharmacology vol. 83
Availability: No items available.
|
|
8.
|
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin. [electronic resource] by
- Maeda, Akimitsu
- Ura, Takashi
- Asano, Chisa
- Haegawa, Ikue
- Nomura, Motoo
- Komori, Azusa
- Narita, Yukiya
- Taniguchi, Hiroya
- Kadowaki, Shigenori
- Muro, Kei
- Horio, Yoshitsugu
- Yoshida, Tatsuya
- Oze, Isao
- Kajita, Masaki
- Mizutani, Akiyoshi
Producer: 20170119
In:
Asia-Pacific journal of clinical oncology vol. 12
Availability: No items available.
|
|
9.
|
Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
. [electronic resource] by
- Maeda, Akimitsu
- Ando, Hitoshi
- Ura, Takashi
- Komori, Azusa
- Hasegawa, Ayako
- Taniguchi, Hiroya
- Kadowaki, Shigenori
- Muro, Kei
- Tajika, Masahiro
- Kobara, Makiko
- Matsuzaki, Masahide
- Hashimoto, Naoya
- Maeda, Mieko
- Kojima, Yasushi
- Aoki, Masahiro
- Kondo, Eisaku
- Mizutani, Akiyoshi
- Fujimura, Akio
Producer: 20171103
In:
International journal of clinical pharmacology and therapeutics vol. 55
Availability: No items available.
|